PainChek Ltd (AU:PCK)
ASX:PCK
Want to see AU:PCK full AI Analyst Report?
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)3.56M
Market Cap
AU$27.17M
Enterprise ValueAU$24.48M
Total Cash (Recent Filing)AU$4.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue & Margin ImprovementConsistent revenue acceleration and improving gross margin point to strengthening unit economics and clearer product-market fit in aged-care settings. If sustained, higher-margin growth can reduce reliance on external capital and improve the path to sustainable profitability as scale increases over coming quarters.
Debt-free Balance SheetHaving no debt reduces fixed financial obligations and lowers near-term default risk, giving management flexibility to prioritise investment or fundraising timing. Over a multi-month horizon this structural advantage preserves optionality while the company addresses cash burn and scaling needs.
Recurring SaaS Model & Market FocusA subscription/usage SaaS model selling into aged care and clinical providers supports predictable, recurring revenue and scalable unit economics. Coupled with structural demographic demand in aged care, this model can drive steady ARR, high retention and efficient incremental margins as deployments expand.
Bears Say
Heavy Cash BurnPersistent negative operating and free cash flow of about -6.8M in 2025 erodes runway and raises near-term financing needs. Sustained cash burn constrains the firm's ability to invest in sales, product development or support, and increases the likelihood of dilutive capital raises absent rapid margin expansion.
Deep UnprofitabilityExtremely negative net and operating margins indicate that scale and current pricing do not cover fixed and operating costs. This structural loss profile means the company requires significant revenue acceleration or material cost restructuring to reach breakeven, a multi-quarter strategic challenge.
Negative Shareholders' EquityEquity turning negative reflects accumulated losses and weakens the capital cushion, limiting borrowing capacity and investor flexibility. Negative equity heightens funding risk, often necessitating equity issuance or other restructuring to restore balance-sheet resilience and reduce solvency concerns.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.13 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$27.17M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 78 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.03%
12-Months-Change
Fundamentals
Return on Equity
-1009.84%
Trailing 12-Months
Asset Growth
7.04%
Trailing 12-Months
Company Description
PainChek Ltd
PainChek Limited specializes in the creation and commercialization of mobile medical applications designed for individual pain assessment. Their core product, PainChek, employs smartphone and tablet cameras to record video, which is then analyzed in real-time by facial recognition software to detect the presence of pain. This technology is particularly beneficial for patients suffering from dementia. The company, which operates from its headquarters in Sydney, Australia, rebranded as PainChek Limited in January 2018, having previously been known as ePAT Technologies Ltd.
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---